DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space Visit Post
2 Follicular Lymphoma Market Size Anticipates Growth as the Key Companies Explores Novel Therapeutics Assets Visit Post
3 Assessing the Opportunities and Challenges in the Oncology Segment Visit Post
4 Evaluating the Present and Future Oncology Market Outlook With Valued Research and Analysis Visit Post
5 Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030 Visit Post
6 Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer Visit Post
7 Systemic Lupus Erythematosus Treatment Market: How the Leading Companies are Countering the Rising Prevalence? Visit Post
8 Reliable Experts in Pharmacology Market: Pharma Consultants Visit Post
9 Business Consultants: An Intense Drive to Work Excellence Visit Post
10 Which Pipeline Therapy is Expected to Capture the Eyeballs in the Phenylketonuria Market? Visit Post
11 Charcot-Marie-Tooth Disease Market Size Expects Growth Owing to Increasing Prevalence, Influx of Pharma Companies and Novel Therapies Visit Post
12 Venous Thromboembolism Market Growth Quadrant to Balloon Up Visit Post
13 Duchenne Muscular Dystrophy Market: What's More Beyond Exon-Skipping Therapies? Visit Post
14 Top 7 Pharma Industry Leaders in 2020 By the Numbers Visit Post
15 Von Hippel-Lindau Market Space Expected to Expand at a CAGR 8.3% by 2030 Owing to Increasing Prevalence and Emerging Therapies Visit Post
16 Fecal Incontinence Therapeutics Market Surges with Innovative Therapies in the Pipeline Visit Post
17 Major Depressive Disorder Market Quadrant Growth Soars Owing to Expected Launch of Key Therapies Visit Post
18 Reimagining Clinical Trials: Why are Virtual Clinical Trials Becoming the New Normal? Visit Post
19 Primary Hyperoxaluria Market Size Observes Growth with a Substantial CAGR Visit Post
20 Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer Visit Post
21 Peanut Allergy Market Outlook: The Market Size Growth Sees Major Thrusts Visit Post
22 Novel Therapies form the Nucleus of the Growth in the Crohn's Disease Therapeutic Market Visit Post
23 Angelman syndrome Pipeline: Unmet needs call for a robust pipeline Visit Post
24 The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market Visit Post
25 Cost-effectiveness, Advanced Technology, Rising Demand Pushes the Insulin Delivery Devices Market Visit Post
26 FemTech Market: With 100+ Startups in the domain, Women Healthcare is Witnessing a Huge Upliftment Visit Post
27 With advancements in Innovative Technology, Cardiac Monitoring Devices Market is Booming Significantly Visit Post
28 JAK Inhibitors Market Visit Post
29 Neurovascular Thrombectomy Devices Market Visit Post
30 Vagus Nerve Stimulators Market Outlook Visit Post
31 Diabetic Macular Edema Therapy Market to Witness Significant Impact in the Foreseeable Future Visit Post
32 What Factors are Shaping the Trends in the Implantable Cardiac Monitors Market? Visit Post
33 How will Pharmacotherapies help the growing number of Presbyopes? Visit Post
34 Mallinckrodt earns FDA nod for skin therapy; RayzeBio secures $108M; VectorY raises $38M; Umoja banks $210M Visit Post
35 Medical Devices Market Blooms as the Key MedTech Companies Continue to Bring-In Innovation Visit Post
36 Spinal Stenosis Devices Market Size to Balloon Up Owing to Increasing Prevalence & Geriatric Population, as well as Medical Advancements Visit Post
37 Continuous R&D Ramps Up the Pacemakers Pipeline Landscape, New Devices To Enter the Market Soon Visit Post
38 What factors are guiding the Growth of Endoscopy Fluid Management Systems in the MedTech Market? Visit Post
39 Essential Demands Impinge the Evolving Adult-onset Still’s Disease Treatment Market Visit Post
40 Which Companies are Vying to get a Major Chunk in the Elastomeric Pump Market? Visit Post
41 Is Antibody-mediated Rejection a Roadblock to Organ Transplantation? Visit Post
42 Who is Going to be a Trendsetter in the Hereditary Deafness Market? Visit Post
43 Renal Tubular Acidosis Therapy Market and Sub-Optimally Effective Standard of Care Visit Post
44 Global Chronic Pain Associated With Painful Diabetic Neuropathy Market Landscape Visit Post
45 Rising Awareness, Key Companies, Emerging Therapies? What is Shaping the Alagille Syndrome Market Visit Post
46 Market Heats Up as Managing Benign Prostatic Hyperplasia Through Devices Gains Traction Visit Post
47 Can We Overlook The Potential Dangers That Come With AI In Healthcare? Visit Post
48 Glioblastoma Multiforme: Advancements in the Treatment Paradigm of the Malignant Condition Visit Post
49 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
50 Sinusitis: Something More Troublesome Than Just Cold Visit Post
51 Pharma Companies Foray into the ABSSSI Market to Develop Novel Antibiotics and Tackle Antibiotic Resistance Visit Post
52 Drug Development and Pipeline Analysis in the Alzheimer’s Disease Market Space Visit Post
53 Ewing Sarcoma: Key Companies and Emerging Therapies in the Landscape Visit Post
54 Alpha-1 Antitrypsin Deficiency: Symptoms, Treatments and Key Companies in the Market Visit Post
55 Limited Therapeutics Options and A Weak Pipeline: What Lies Ahead in the Cancer Anorexia Market? Visit Post
56 E-Pharmacies: A Disruptive Innovation and the Future of Pharma Sector Visit Post
57 Kinase Inhibitors: Challenging the established Biologics as the new standard of care in autoimmune diseases? Visit Post
58 A New Addition to Existing Chimeric Antigen Receptor Therapies –Potential for a Game Changer in Blood Cancers Visit Post
59 Ever-Evolving Market Landscape of Transcatheter Aortic Valve Replacement Visit Post
60 How Will New Discoveries of Deep Brain Stimulation Devices Transform the Pharma Domain? Visit Post
61 Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? Visit Post
62 Navigating Through the Treatment Market Landscape of Head and Neck Cancers Visit Post
63 Hemophilia B Market: How Pipeline Therapies are Transforming the Treatment Hemisphere? Visit Post
64 Emerging Therapies in the Chronic Pain Pipeline Transforming the Chronic Pain Market Landscape Visit Post
65 A Royal Disease: Hemophilia Visit Post
66 Rare Cancer Market: A Global Crusade on what is a ‘less common cancer’? Visit Post
67 What are the Market Drivers Fueling the Rare Disease Market? Visit Post
68 Gene and Cell Therapies in CNS Disorders: Miracle Cure? Opportunities Galore! Visit Post
69 Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset Visit Post
70 Emerging Research Continues To Transform Erythropoietic Protoporphyria Market Outlook Visit Post
71 Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities Visit Post
72 Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda's Maribavir; Astellas/Seagen Padcev Visit Post
73 The Paradox of Rare: Chalking out Challenges in the Rare Disease Market Visit Post
74 Limited Therapies in the Rare Disease Pipeline: Watch out for Rare Indications that Calls Out for Novel Therapies Visit Post
75 Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia Visit Post
76 Cystic Fibrosis Market: A Rapidly Expanding Playing Field for Mid-Cap Pharma Visit Post
77 The Mesh of the Generics and the Potential of Emerging Therapies in the Smoking Cessation Market Visit Post
78 Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs Visit Post
79 Notorious Hyperkalemia: What are the causes, signs and new treatments? Visit Post
80 A Bleak Pipeline and Lack of Approved Treatment Clouds the Hemophagocytic Lymphohistiocytosis Market Size Growth Visit Post
81 Thrombocytopenia Drugs Market: What Newer Agents Are Expected To Enter The Market? Visit Post
82 We’re all in this together! Visit Post
83 Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder Visit Post
84 A Need for Curative Treatment Expected to Attract the Pharma Players in the Hallux Valgus Market Landscape Visit Post
85 Parkinson's Disease: How close are we to a cure? Visit Post
86 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
87 Search for the Cure Continues in the Chronic Hepatitis B Treatment Market Visit Post
88 Unmet Needs and Emerging Trends in the Acute Respiratory Distress Syndrome Market Landscape Visit Post
89 Watch Out For Top Pipeline Therapies Making An Impact In The Bipolar Depression Market Visit Post
90 Top 10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape Visit Post
91 13 of the most commonly asked questions about Glioblastoma multiforme, Answered Visit Post
92 21 of the most common questions about Epilepsy Visit Post
93 Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Visit Post
94 Treating Patients with Software: Digital Therapeutics Visit Post
95 Creating Future of MedTech Industry with Artificial Intelligence Visit Post
96 Advancements in Neuromodulation Visit Post
97 Rheumatoid Arthritis: Causes, Risk Factors, Treatment Approaches and Market Landscape Visit Post
98 Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market Visit Post
99 What are the options available for the treatment of Retinal vein occlusion? Visit Post
100 Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market Visit Post
101 Biliary Tract Cancer: Emerging Players in the Market Transforming the Treatment Landscape Visit Post
102 Ever-evolving Market Dynamics of Epilepsy – a silver lining! Visit Post
103 The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach Visit Post
104 Key Pharma Players Transforming the Complement 3 Glomerulopathy Market Landscape Visit Post
105 Argininosuccinic Aciduria Market Awaits Innovative Treatment Expected To Launch In The Next Decade Visit Post
106 Trump vs. Biden: What is in Store for Healthcare Domain? Visit Post
107 Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size Visit Post
108 Which pipeline therapy has the potential to revolutionize the Down Syndrome Market? Visit Post
109 7 Most Common Myths About Breast Cancer Demystified Visit Post
110 Key Facts To Know About Triple-Negative Breast Cancer In The Breast Cancer Awareness Month Visit Post
111 The Growing Burden Of Neurodegenerative Disorders Visit Post
112 Breast Cancer: Understand your breasts, recognize the symptoms Visit Post
113 Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years Visit Post
114 Key Pharma Players Changing The Dynamics Of Schizophrenia Market Visit Post
115 Key Companies To Keep an Eye on for Pipeline Therapies in Osteosarcoma Market in the Next Decade Visit Post
116 Pitfalls of Current Osteosarcoma Treatment Approaches Visit Post
117 Conditions Medical Marijuana is Anticipated to be Prescribed in the Offing Visit Post
118 Inovio's COVID vaccine trial On-hold; Appeal to Pfizer; XtalPi's massive raise; GSK Nucala's HES approval; J&J's COVID vaccine Visit Post
119 Glioblastoma Multiforme Market: Emerging Pipeline Therapies To Keep A Keen Eye On Visit Post
120 Huge Unmet Needs in the Glioblastoma Multiforme Treatment Market Driving the Market Size Growth Visit Post
121 Roadblocks In The Peripheral Nerve Injury Market Require A Multi-faceted Approach Visit Post
122 Cervical Cancer Market Has A Lot Going On Under The Hood Visit Post
123 Preventing Cervical Cancer Through Screening And HPV Vaccines Visit Post
124 What Does The Acromegaly Pipeline Have Up In Its Sleeve? Visit Post
125 Cycle Pharmaceuticals' USD 25M Debt Financing; Bayer’s Phase IV REPLACE Trial; Verona's Pilot Study with pMDI Ensifentrine in COVID Patients Visit Post
126 Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse Visit Post
127 Keratoconus - Rare? Not really! Visit Post
128 Do We Have A Cure For Rosacea? Visit Post
129 The Rarity Of Dravet Syndrome: Challenges, and Treatments Visit Post
130 What Can Help Manage The Insufficient Pancreas? Visit Post
131 Interstitial Cystitis: A big opportunities for emerging drugs Visit Post
132 Sanofi acquires Principia; FDA's Nod to Roche's Enspryng; BMS, Dragonfly's Licensing Deal Visit Post
133 New Hopes; New Horizons: Gastroparesis Market Has Mighty Treatment Options On Its Sleeves Visit Post
134 Celiac Disease: The Hidden Epidemic of Gluten Sensitivity Visit Post
135 How GSK, Chiesi Farmaceutici, Regeneron/Sanofi, Novartis, and AB Science are trying to benefit patients afflicted with Inadequately Controlled Asthma? Visit Post
136 Infectious Diseases That Possess Significant Challenge To Humans Health Visit Post
137 Boehringer Ingelheim; Roche demonstrated new analyses of their drugs in patients with ILDs during the American Thoracic Society (ATS) Virtual conference Visit Post
138 Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference Visit Post
139 Medical Marijuana: Is it a blessing in disguise or a curse for humanity? Visit Post
140 Unfolding The Folds Of Transthyretin Visit Post
141 Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia Visit Post
142 A Complex Chromosomal Abberation Called Adrenoleukodystrophy Visit Post
143 Addressing The Scattered Harbingers of Frontotemporal Dementia Visit Post
144 Rejections and Withdrawals: Familial Chylomicronemia Syndrome Market Needs a Therapy Effective Enough, Affordable Enough Visit Post
145 Ways IoT Has Transformed The Pulse Of Healthcare, And Will Continue To Do So In The Future Visit Post
146 Watch Out for the Most Promising Therapies in the Pipeline in Acute Kidney Injury Market Visit Post
147 An Eye-Blinding Scenario of Vernal keratoconjunctivitis Visit Post
148 Metabolic Acidosis: Counting The Unmeasured Anions And Closing the Gap In Blood Serum Visit Post
149 Spot the Signs and Fight Postpartum Depressions Visit Post
150 Rising Nontuberculous Mycobacterial Infection Prevalence Poses A Major Public Health Concern Visit Post
151 Small Cell Lung Cancer Market Booms with an Influx of Companies and Robust Pipeline Visit Post
152 Top 5 Cancers Creating Major Challenge To The Global Healthcare System Visit Post
153 In Search for a Curative Treatment Option for Duchenne Muscular Dystrophy Visit Post
154 The Increasing Global Burden of Cytomegalovirus Seroprevalence Visit Post
155 Mapping The Pipeline Development In The Geographic Atrophy Market Visit Post
156 Paradigm Shift In The Diabetic Peripheral Neuropathy Market Landscape As The Focus Shifts Towards The Cure Visit Post
157 How are Diabetic Peripheral Neuropathy medications changing the DPN market scenario? Visit Post
158 Can Aducanumab Slove the Puzzle Of Alzheimer’s? Visit Post
159 When Technological Innovations Help in Remembering for People Living with Alzheimer’s Visit Post
160 With the Advances in Regenerative Therapy to Offer Curated Treatment Options, Off-label Therapy Market is Set to Decline for Dilated Cardiomyopathy Visit Post
161 Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead Visit Post
162 An Ageing Population and Upcoming Therapies: What is shaping the Alzheimer’s Disease Market Scenario? Visit Post
163 One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline Visit Post
164 Precision Medicine: An emerging approach to conventional treatment Visit Post
165 R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia Visit Post
166 Hunter Syndrome Market experiences a positive push as the pharma companies spot the untapped opportunities Visit Post
167 Keeping a track on COVID-19 through Wearable Technology Visit Post
168 Is the cure for Duchenne Muscular Dystrophy in the pipeline? Visit Post
169 Emerging Therapies that can significantly impact the Acute Kidney Injury Market Visit Post
170 Security Breach: A Growing Concern For The Healthcare Industry Visit Post
171 Is the cure for Huntington’s disease on the horizon? Visit Post
172 Overcoming the prevailing unmet needs in Beta-Thalassemia Market Visit Post
173 Altering the course of Ovarian cancer with emerging therapies in the horizon Visit Post
174 Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses Visit Post
175 Telehealth: Opportunities and Hurdles in Virtual Healthcare Market Visit Post
176 Chemotherapy Induced Febrile Neutropenia Market: High time to end the monopoly Visit Post
177 Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines Visit Post
178 Novel coronavirus crumbles down as soon as it lands on copper Visit Post
179 CAR-T cell therapy market for Non-Hodgkin lymphoma: Future prospects, and untapped opportunities Visit Post
180 Supply shortage: Why ventilators are in demand amid the Coronavirus crisis Visit Post
181 Is Hydroxychloroquine the answer to all the COVID-19 questions? Visit Post
182 Future Perspectives Of CAR-T Cell Therapy Market In Acute Lymphoblastic Leukemia (ALL) Visit Post
183 COVID-19 crisis can prove to be a catalyst for Artificial Intelligence in Healthcare Visit Post
184 Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs Visit Post
185 Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast Visit Post
186 Telemedicine: Can it be the future of healthcare? Visit Post
187 Realm of Pandemics: Were we prepared then? Are we prepared now? Will we be ever prepared? Visit Post
188 What is driving Retinitis pigmentosa market forward? Visit Post
189 Bioelectronic Medicine: Applications and Future Prospects Visit Post
190 Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence Visit Post
191 Soft Tissue Sarcoma Market size to increase with a CAGR of 6.47% – Emerging therapies and Increasing Incidence form major market drivers Visit Post
192 Should you wear contact lenses amid coronavirus outbreak? Visit Post
193 Dubai: A leading and exciting pharma hotspot Visit Post
194 Questions and Answers on the Novel Coronavirus Disease (COVID-19) Visit Post
195 Soft Tissue Sarcoma Treatment Market: Present treatment approaches and Unmet Needs Visit Post
196 Top healthcare innovations changing the healthcare dynamics Visit Post
197 Soft Tissue Sarcoma: A rare malignancy Visit Post
198 Gene therapy might make cocaine less addictive Visit Post
199 Opioid Withdrawal Syndrome Pipeline: What lies in the future for those facing withdrawal symptoms Visit Post
200 Opioid Withdrawal Syndrome: What happens when a person withdraws from Opiates Visit Post
201 Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players Visit Post
202 Why should every company working on CAR-T therapy attend CAR TCR Summit Europe? Visit Post
203 Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade Visit Post
204 Wet Age-Related Macular Degeneration: Unravelling the complex disease with comprehensive R&D Visit Post
205 The epidemic now has a name: COVID-19 Visit Post
206 Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline Visit Post
207 How Artificial Intelligence is adding value to the Healthcare sector Visit Post
208 Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development Visit Post
209 Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver Visit Post
210 Wuhan Coronavirus: A global emergency Visit Post
211 Thyroid eye disease market: New therapies enter the TED market Visit Post
212 In a blind race to cure HIV, can Gene therapy be a deal-breaker? Visit Post
213 Malignant Pleural Mesothelioma Upcoming Therapies Visit Post
214 Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis Visit Post
215 Anaphylaxis: A Rare Disease Visit Post
216 Marijuana as a treatment approach Visit Post
217 Egg Allergy Market: Second most common food allergy but no approved therapy Visit Post
218 Chronic Hand Eczema Market Analysis and Forecast Visit Post
219 Angelman syndrome: A Rare Genetic Disorder Visit Post
220 Atopic dermatitis market and a Dupilumab dominance Visit Post
221 Atopic dermatitis market: Increasing prevalence and topical treatments Visit Post
222 Allergic rhinitis market: How common is Hay fever? Visit Post
223 Global Allergic disease market Visit Post
224 Autologous cell therapy market: A new paradigm for kidney diseases Visit Post
225 Reversing Ischemia with Gene therapy Visit Post
226 Schizophrenia vs Bipolar disorder: Biomarkers to the rescue Visit Post
227 Increasing cases of Mania and Bipolar disorder market Visit Post
228 Fragile X Syndrome Market Visit Post
229 Gaucher disease Market Analysis: Rich Pipeline Drives the Market Ahead Visit Post
230 Are Rare Diseases truly Rare? Visit Post
231 Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval Visit Post
232 The Regulatory process for drug approval in the MENA region Visit Post
233 Chronic Refractory Cough Market landscape: A new approach to treating cough Visit Post
235 How Gene therapy is changing the Beta-thalassemia Treatment outlook? Visit Post
236 The long journey of Biosimilars: Is it an emerging opportunity? Visit Post
237 Complex Regional Pain Syndrome Upcoming Therapies Visit Post
238 Is Air Pollution a driver in COPD Treatment Market? Visit Post
239 Parkinson’s Disease Market: Impact of Emerging therapies on Parkinson’s therapeutics market Visit Post
240 Metastatic Pancreatic Cancer Market Size: Emerging therapies, Unmet needs and Forecast analysis Visit Post
241 Non-Small Cell Lung Cancer Market: Treatments and Market Forecast Visit Post
242 Refractory Metastatic Melanoma Market Visit Post
243 Onychomycosis therapeutics market: Impact of new topical anti-fungal drugs Visit Post
244 Emerging drugs bring a positive shift in Global Osteoporosis Market Visit Post
245 New Therapeutic advances that have shifted the Breast cancer market scenario Visit Post
246 HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis Visit Post
247 First oral GLP-1 treatment approved for type2 Diabetes Visit Post
248 FDA approves Bonsity for Osteoporosis treatment Visit Post
249 A New Era for Migraine Treatment and CGRP antibodies Visit Post
250 FDA is reviewing a dangerous way to treat Peanut Allergy Visit Post
251 Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis Visit Post
252 How HR+/ HER2-Breast Cancer emerging drugs will transform the market? Visit Post
253 Global HR+/ HER2- Breast Cancer Market Scenario Visit Post
254 Japan is transforming its Healthcare sector through Regenerative Medicine Visit Post
255 FDA approves Ofev for interstitial lung disease Visit Post
256 Metastatic HER2-Positive Breast Cancer Visit Post
257 Allergic Conjunctivitis Therapy Market and Pipeline Analysis Visit Post
258 How Spinal Muscular Atrophy Therapies transform market? Visit Post
259 What lies in the future for NASH upcoming drugs? Visit Post
260 What to expect in the Coming Years for Hairy Cell Leukemia Therapy landscape? Visit Post
261 Imfinzi fails. What’s next in Non-small cell lung cancers Market Scenario? Visit Post
262 Leber Hereditary Optic Neuropathy Treatment Market Visit Post
263 Chemotherapy-Induced Peripheral Neuropathy Market Trends Visit Post
264 Psoriasis Pipeline: Upcoming Psoriasis Treatments Visit Post
265 Psoriasis Therapy Market Size  Visit Post
266 Niemann–Pick disease type C Therapeutics Market Visit Post
268 Diabetic Gastroparesis Market Outlook Visit Post
269 Global Hepatitis B Market Size Visit Post
270 Parkinson's Disease: 5 stages, Risk Factors, Prevention, Gene Therapy Visit Post
271 Juvenile Idiopathic Arthritis Therapy Market Visit Post
272 Juvenile Idiopathic Arthritis Etiology and Epidemiology Visit Post
273 Idiopathic Pulmonary Fibrosis –Scarring For A Lifetime Visit Post
274 Myelofibrosis Therapeutics Market Visit Post
275 Cutaneous T-cell lymphoma Market Outlook Visit Post
276 Generalized Pustular Psoriasis Market Visit Post
277 Chronic Lower Back Pain Market Analysis Visit Post
278 Chronic Lower Back Pain Therapy Market Visit Post
279 Myasthenia gravis Market Outlook Visit Post
280 Pompe Disease Scenario in Eastern Europe Visit Post
281 Pompe Disease Emerging Markets Visit Post
282 The era of Gene therapy, and the Billion Dollar tag Visit Post
283 Pompe Disease Treatment Market Visit Post
284 Pompe Disease Market Visit Post
285 What is the link between Alzheimer's and Menopause? Visit Post
286 Antihypertensive drugs decrease Dementia rate Visit Post
287 Global Neuroendocrine Tumor Market Outlook Visit Post
288 What is causing a rise in Autism rate? Visit Post
289 NASH Emerging Therapies Visit Post
290 Pulmonary Arterial Hypertension Therapies Visit Post
291 Unmet Needs in the treatment of Antitrypsin deficiency Visit Post
292 Acne Vulgaris Market Outlook Visit Post
293 Acute Bacterial Skin and Skin Structure Infections Emerging Therapies Visit Post
294 ABSSSI Current Therapeutic Market Visit Post
295 Spinal Muscular Atrophy Market Visit Post
296 Ovarian Cancer Treatment Drugs and Unmet Needs Visit Post
297 Spinal Muscular Atrophy: Current and Emerging Therapies Visit Post
298 Spinal Muscular Atrophy Market is expected to augment at a CAGR of 10.42% Visit Post
299 Global Parkinson’s Therapeutic Market Outlook Visit Post
300 Can commoners afford to spend million dollars on GENE Therapy? Visit Post
301 Beta Interferons prolongs life in Multiple Sclerosis Visit Post
302 New Osteoporosis Drug promises to rebuild Bone Visit Post
303 Gene Therapy in Oncology: Innovation to Commercialization Visit Post
304 Current and Emerging therapies that change Traveler’s Diarrhea Market Visit Post
305 What can be the scope of Medical Marijuana? Visit Post
306 Boys are more likely to have autism! Visit Post
307 Global Traveler's Diarrhea Market Visit Post
308 EPILEPSY- A Neurological Disorder Visit Post
309 Complex regional pain syndrome (CRPS)-A debilitating disease Visit Post
310 Narcolepsy now a confirmed Autoimmune Disorder Visit Post
311 The changing landscape of Multiple Myeloma therapies market Visit Post
312 Where Women Healthcare Stands Visit Post
313 Wearing Technology to stay fit Visit Post
314 Cost ineffective Orphan Drugs limit the access Visit Post
316 What is Cholangiocarcinoma (CCA)? Visit Post
317 Human cells reprogrammed to create insulin in diabetic mice Visit Post
318 Raynaud's Disease -A debilitating condition Visit Post
319 Acromegaly Visit Post
320 Myasthenia Gravis Visit Post
321 Neuroendocrine Tumors (NETs) Visit Post
322 Molecular Profiling Could Help in Early Lung Cancer Detection: Study Visit Post
323 Artificial Intelligence face-scanning app spots signs of rare genetic disorders Visit Post
324 Where in the world could the first CRISPR baby be born? Visit Post
325 Cervical cancer: What you need to know Visit Post
326 ‘Transmissible’ Alzheimer’s theory gains traction Visit Post
327 Attention-Deficit/Hyperactivity Disorder (ADHD) Visit Post
328 Baby gene edits could affect a range of traits Visit Post
329 Does coconut oil help prevent dementia? Visit Post
330 Researchers say CRISPR edits to a human embryo worked Visit Post
331 The lab-grown mini-brains generate electrical patterns Visit Post
332 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
333 ‘Invisible’ mice reveal anatomical secrets Visit Post
334 Calciphylaxis: Rare Yet Potentially Fatal Visit Post
335 Meeting the Unmet Need for Oral Mucositis Visit Post
336 Can GABA turn pancreatic α-cells into β-cells? Visit Post
337 Biologic Parallel – A Perky Future Ahead Visit Post
338 Neuroendocrine tumors (NETs): The complex group of tumors Visit Post
339 Digital Pill: A new frontier in digital healthcare all set to take-off Visit Post
340 China Preparing for Pharma Big Bang: Is this Alarm Bell for US, Euro Pharma Giants? Visit Post
341 Japan Manages to Stand Apart from Global Hepato Cellular Carcinoma Crowd Visit Post
342 Idiopathic Pulmonary Fibrosis (IPF) – When to start and what is coming in the race to treat the deadlier constricts…. Visit Post
343 Voltage-Dependent T-Type Calcium Channel Blockers  Visit Post
344 Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care Visit Post
345 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window Visit Post
346 Niemann-Pick disease type C (NPC) -A Rare Cognitive Decline Indication Visit Post
347 Allergic Conjunctivitis (AC)- Market Insights, Epidemiology and Market Forecast- 2027 Visit Post
348 Allergic Conjunctivitis (AC) – Common disorder with increasing prevalence Visit Post
349 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential Visit Post
350 Hepatic Encephalopathy- An ailment of liver to brain Visit Post
351 NF-κB Inhibitors- A Promising Future Visit Post
352 Hematopoietic Stem Cell Transplantation Visit Post
353 STAT INHIBITORS- Highly active Pipeline Visit Post
354 Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment Visit Post
355 Hepatic Encephalopathy- Lack of active pipeline products Visit Post
356 Hyperuricemia – Uric acid disorder, a gateway to other diseases Visit Post
357 Celiac Disease – Intestinal damage of Gluten Visit Post
358 Transthyretin Amyloidosis (ATTR) Competitive Landscape, Market Insights, Epidemiology and Market Visit Post
359 Nonalcoholic Steatohepatitis (NASH): Highly Epidemic Visit Post
360 Meeting the Unmet: Nonalcoholic Steatohepatitis (NASH) Visit Post
361 Immune Checkpoint Activators (ICA): Dynamic Therapeutic Targets Visit Post
362 Natural Killer Cell Therapies: An Emerging Cellular Therapy Visit Post
363 Involvement of B cells in the pathogenesis of primary Sjögren syndrome (pSS) Visit Post
364 Familial Amyloid Polyneuropathy – An uncommon medical condition Visit Post
365 Hereditary Angioedema (HAE) – Active drug pipeline Visit Post
366 Systemic Lupus Erythematosus (SLE) – Market Is Expected to Grow with Upcoming Therapies Visit Post
367 Gaucher Disease: “Rare Disorder with High Unmet Needs” Visit Post
368 Toll-Like Receptor Modulators: Emerging therapy for many indications Visit Post
369 Celiac Disease (CD) – Upcoming therapies to break the stagnancy Visit Post
370 Targeting cancer through CD40 agonists -A promising future Visit Post
371 Bubble Boy Syndrome (ADA-SCID) - A Rare Immunodeficiency Disorder Visit Post
372 Wiskott - Aldrich syndrome – a rare X-linked disorder Visit Post
373 Metachromatic Leukodystrophy (MLD): A Rare Indication with great unmet medical need Visit Post
374 Wet AMD: A chronic eye condition with promising therapies Visit Post
375 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
376 Isocitrate dehydrogenase (IDH) inhibitors– Emerging Anti-Cancer Therapeutics Visit Post
377 Oral Mucositis – A Common Cancer Therapy Adverse Reaction Visit Post
378 Human Papillomavirus (HPV) Prophylaxis– Expected to see a steady growth from 2015-2025 Visit Post
379 HDAC (Histone Deacetylase) Inhibitors – A Promising Anti-Cancer Target Visit Post
380 Amyotrophic Lateral Sclerosis (ALS) a fatal disease! Visit Post
381 Bruton's Tyrosine Kinase (BTK) Inhibitors An Emerging Therapeutic Target Visit Post
382 PARP Inhibitors making inroads into Ovarian Cancer Visit Post
383 Friedrich's ataxia: Rare disease Visit Post
384 Natural Killer Cell Therapies– Advancing technology increasing competition among the companies Visit Post
385 CDK 4/6 Inhibitors- The Changing Paradigm for Breast Cancer Treatment Visit Post
386 Interstitial Cystitis : Promising Scope for Research Visit Post
387 Actinic Keratosis – A Warning Sign for Potential Skin Cancer Visit Post
388 Urinary Tract Infections (UTIs)– How is it affecting the Globe? Visit Post
389 Vitiligo – High Unmet Need Indeed! Visit Post
390 Progressive Supranuclear Palsy– A neurodegenerative disorder Visit Post
391 Cutaneous Squamous Cell Carcinoma Market & pipeline Visit Post
392 Insight on Interstitial Cystitis- The Bladder Pain Syndrome Visit Post
393 Hemophilia: A Lifelong Genetic Disorder Visit Post
394 Urinary Incontinence: Epidemiology Insight on Leaking Bladder Visit Post
395 Non-Hodgkin Lymphoma: “Malignant Growth of White Blood Cells” Visit Post
396 Chemotherapy-Induced Nausea and Vomiting Side effects Visit Post
397 Acromegaly and Gigantism: It’s all about excessive Growth Hormone… Visit Post
398 Hemophilia A- Market Scenario Visit Post
399 Narcolepsy: Treatment options and market outlook Visit Post
400 Sarcopenia: “Aging-Associated Strength Loss Condition” Visit Post
401 The Current Scenario for Interstitial Cystitis(IC) Visit Post
402 AKT Inhibitors: A potential Cancer Immunotherapy Target Visit Post
403 Medical tourism in India Visit Post
404 Epidemiology: Fatty Liver Disease Visit Post
405 Colorectal Cancer Market Analysis and Market Forecast Visit Post
406 Vulvovaginal Candidiasis Visit Post
407 Colony Stimulating Factor 1 Receptor (CSF1R) and Its connection with Memory Retention Visit Post
408 Cushing’s Syndrome: Cortisol Plethora Visit Post
409 Follicle Stimulating Hormone for treatment of Endometriosis Visit Post
410 Cytomegalovirus infection Market Visit Post
411 Fragile X syndrome: X-linked mental retardation and macroorchidism Visit Post
412 Microbiome- A Living Therapy from Guts to Cancer Visit Post
413 Biosimilars: A benchmark in Pharmaceutical Business Visit Post
414 mTOR Inhibitors-Emerging therapy in various therapeutic areas Visit Post
415 NMDA Receptor Antagonist: Emerging therapies in CNS Visit Post
416 Angina Pectoris : Manifestation of Coronary Artery Disease Visit Post
417 Science Events of the Year Visit Post
418 Systemic Lupus Erythematosus: An autoimmune disease Visit Post
419 Chronic Obstructive Pulmonary Disease (COPD): Scenario Visit Post
420 Ovarian Cancer: The Silent Killers Visit Post
421 Most Common Cancers Visit Post
422 Physician Confronts Reviewer Who Stole Study Visit Post
423 Cliche can be described as a wonderful strategy. Visit Post
424 Obsessive-Compulsive Disorder: Emerging Therapies Visit Post
425 Sjogren's syndrome- Autoimmune Attack on Salivary and Tear Glands Visit Post
426 On World AIDS Day... Visit Post
427 Vasomotor Symptoms of Menopause-Emerging Therapies Visit Post
428 High Risk Smoldering Multiple Myeloma Visit Post
429 Idiopathic Pulmonary Fibrosis: Recent Scenario Visit Post
430 Phosphoinositide 3-Kinase (PI3k) Inhibitors: Emerging target therapies against Cancer Visit Post
431 Estrogen Receptor Positive Breast Cancer: Market Outlook Visit Post
432 Merck’s Antibody for Clostridium Difficile Visit Post
433 Neprilysin Inhibitor for Cardiovascular Diseases Visit Post
434 Medivir & Karo Pharma’s deal; Astellas acquires Ganymed; Celldex Acquires Kolltan; Allergan to Acquire Motus Therapeutics Visit Post
435 Biosimilar Market in India Visit Post
436 Sarepta’s Unusual Journey Visit Post
437 Dengvaxia: Boon for Dengue Visit Post
438 JAK Inhibitors: New Lifeline for Hair Loss Treatment Visit Post
439 Liquid Biopsy: Revolutionary Technique for Cancer Diagnosis Visit Post
440 DelveInsight’s Launch of Its New & Improved Report Store Visit Post
441 Taltz (Ixekizumab) in Treatment of Plaque psoriasis Visit Post
442 Cervical Cancer: Current Scenario Visit Post
443 Graft vs Host Disease (GVHD): Treatment approaches and Trends Visit Post
444 Futuristic Customizable RNA Vaccine Visit Post
445 Recent Pharma Developments related to Immune Checkpoint Activators Visit Post
446 BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate Visit Post
447 PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment Visit Post
448 Nav1.7 Blockers- New Genre of Pain Relief Therapy Visit Post
449 Pharm Delve Cognizance Visit Post
450 Spinal Muscular Atrophy Emerging therapies Visit Post
451 A promising immune-stimulating target Visit Post
452 Anticoagulants (VTE & AF) Therapeutics Market Visit Post
453 Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 Visit Post
454 Global VTE market is expected to grow to $4.75 billion by 2020 Visit Post
455 Anticoagulants-Market Insights; Drugs Sales Forecast (VTE & AF) Visit Post
456 Pancreatic Cancer Market Insights, Epidemiology and Market Forecast-2020 Visit Post
457 Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
458 Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
459 Hemophilia - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
460 Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
461 Duchenne Muscular Dystrophy Market Visit Post
462 Acute Myeloid Leukemia- Market Insights, Epidemiology & Forecast Visit Post
463 Rheumatoid Arthritis Market, Epidemiology and Market Forecast-2020 Visit Post
464 Indication-Market Insights, Epidemiology and Market Forecast,2010-2020:DelveInsight's New Launch Visit Post
465 Antibody-Drug Conjugate Market Insight Visit Post
466 PD-1 and PD-L 1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2016 Visit Post
467 LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 - A DelveInsight Report Visit Post
468 Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast Visit Post
469 Zemplar Drug Insights, 2016 Visit Post
470 Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 Visit Post
471   Pancreatic Cancer-Pipeline Insights, 2016 Visit Post
472 Peripheral Lung Cancer Pipeline Insights, 2016 Visit Post
473 DelveInsight's Market Research Reports Visit Post
474 Small interfering RNA (siRNA) Therapeutics Visit Post
475 Fatty Acid Amide Hydrolase (FAAH) Inhibitors - Pipeline Insights, 2015 - A DelveInsight’s Report Visit Post
476 Orphan drug development strategies Visit Post
477 New Approach Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Visit Post
478 “Endometrial Cancer - Pipeline Insights, 2015”- A DelveInsight’s Report Visit Post
479 PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015 - A DelveInsight Report Visit Post
480 Systemic Juvenile Idiopathic Arthritis -Pipeline Insights, 2015 Visit Post
481 Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 Visit Post
482 Oral Mucositis Pipeline Insights, 2015- A DelveInsight Report Visit Post
483 Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Analysis Visit Post
484 DelveInsight’s Oncology based Reports, 2015 Visit Post
485 DelveInsight launches Indication Active Pharmaceutical Ingredient (API) Reports Visit Post
486 Chimeric Antigen Receptor T cell Therapy Market Visit Post
487 Chimeric Antigen Receptor T-cell Therapy Landscape Visit Post
488 DelveInsight Hiring Analysts and Associate Analysts Visit Post
489 Outbreak of Companies Challenging New Pathways for Treatment of Pulmonary Arterial Hypertension Visit Post
490 Telomerase Inhibitors – An Anti Cancer Approach Visit Post
491 A Glimpse of the Anticoagulants Therapy Market; Major Players Visit Post
492 Emergence of Stem cells and its Market Impact Visit Post
493 PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2015 Visit Post
494 Anticoagulants Market A Big Boom Visit Post
495 Antibody-Drug Conjugate and Big Pharmaceutical Companies Visit Post
496 What are your views on Gene Therapy? Visit Post
497 Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now! Visit Post
498 Next Generation Antibody-Drug Conjugate Therapeutics and Market Analysis Visit Post
499 Antibody-Drug Conjugates Market Outlook, 2015 Report Visit Post
500 DelveInsight Hiring!!!! Visit Post
501 Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Visit Post
502 Gene Therapy to “Assassinate” HIV virus Visit Post
503 Suicide Gene Therapy: Where do we stand? Visit Post
504 DelveInsight’s Gene Therapy Reports: Launched Visit Post
505 A CRISPR-Cas9 approach for Gene Therapy: The Hot New R&D Field! Visit Post
506 Gene Therapy’s Emergence: The “New” approach for Huntington’s disease Visit Post
507 Are you ready to embrace Gene Therapy? Visit Post
508 DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports Visit Post
509 DelveInsight’s Hematological disorders based Gene Therapy Reports Visit Post
510 DelveInsight’s Respiratory disorders based Gene Therapy Reports Visit Post
511 DelveInsight’s Immunology based Gene Therapy Reports Visit Post
512 DelveInsight’s Cardiovascular disorders based Gene Therapy Reports Visit Post
513 DelveInsight’s Musculoskeletal disorders based Gene Therapy Reports Visit Post
514 DelveInsight’s Metabolic disorders based Gene Therapy Reports Visit Post
515 DelveInsight’s Infectious disorders based Gene Therapy Reports Visit Post
516 DelveInsight’s Gastrointestinal based Gene Therapy Reports Visit Post
517 DelveInsight’s Genetic disorders based Gene Therapy Reports Visit Post
518 DelveInsight’s Dermatology based Gene Therapy Reports Visit Post
519 DelveInsight’s Genitourinary Sex hormones based Gene Therapy Reports Visit Post
520 DelveInsight’s Central Nervous System Disorders based Gene Therapy Reports Visit Post
521 DelveInsight’s Otolaryngology based Gene Therapy Reports Visit Post
522 DelveInsight’s Oncology based Gene Therapy Reports Visit Post
523 Break the Gene Therapy Barrier with DelveInsight’s Gene Therapy Reports Visit Post
524 Gene Therapy Market Visit Post
525 API Manufacturers Across the Globe: Market Intelligence Report Visit Post
526 Global Hemophilia Market Visit Post
527 Our Formula For Mechanism Of Action Is So Effective We’d Patent It If We Could Visit Post
528 Infectious Disease and Vaccines Pipeline Reports Visit Post
529 Ebola Virus Drugs Approved or Still in Pipeline. What’s the mystery? Visit Post
530 Metastatic Prostate Cancer-Pipeline Insights, 2014 Visit Post
531 Brain Hemorrhage-Pipeline Insights, 2014 Visit Post
532 Rheumatoid Arthritis Market Analysis Visit Post
533 DelveInsight’s Marketed and Pipeline Reports Going Viral! Visit Post
534 Oncology Therapeutics Making Big in Coming Years Visit Post
535 Compare the Global Sales of Blockbuster Drugs Losing Patent in 2014 Visit Post
536 Celecoxib first Generic Approval to Teva and Mylan from FDA Visit Post
537 EMA Biosimilars Approvals Visit Post
538 DelveInsight- Business Consultant and Knowledge Partner Visit Post